Weight Loss Stomach Pump Market - Latest trends in Healthcare Industry: Future trends and Market Forecasts by 2024

Weight loss stomach pump is a device which provides effective control over the calorie absorption by the body. It is an external pump that spill of stomach contents into the toilet. The device is a minimally invasive which includes a tube that goes inside the stomach to port outside. The device is used to lose weight easily than people who use to have controlled diets, surgery or batch of devices to make the stomach smaller. Patients need to be regularly monitored by the health care provider and should be guided by a diet consultant in order to reduce their calorie intake.  As per the clinical trials reports, the average patient observe a loss in 46 pounds in the first year and 50 pounds in the following year. 

Get Free PDF Brochure for more Professional and Technical insights – 2024: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=13664

Weight loss stomach pumps are usually utilized by bulimia or assisted bulimia patients of an age 22 or more. Weight loss stomach pump usage are expected to grow at a high rate owing to increase in a patient with more obesity problem and bypass gastric surgery. Weight loss stomach pump market is expected to grow at a significant CAGR due to their ability to lose the weight of the body with minimum invasiveness. Moreover, an increase in obesity and bulimia patients, fewer side effects, develop in life style habits, and increase in non-surgical treatment worldwide will also support the market growth. However, side effects associated with surgery are certain challenges which may hamper the market of weight loss stomach pump.

The weight loss stomach pump market has been segmented by disease type, by end-user, and by geography. In terms of disease type, the weight loss stomach pump market has been categorized into anorexia, bulimia, and diabetes. Unhealthy lifestyle is influencing in increasing obesity associated diseases among healthy habitat. Hence, weight loss stomach pump would play a major part in an effectively control over obesity. The end-users for the market include hospitals, nursing homes, clinics, and others. The weight loss stomach pump provider’s offer specialized programs to the end-users assisting in management of health plans by offering solutions to increasing costs of complexities during treatment.

Geographically, weight loss stomach pump market is segmented into two major regions: North America, and Europe. North America was observed to be the largest weight loss stomach pump market due to extensive technological advancements in the region. Countries such as the U.S. and Canada have been successful in implementing weight loss stomach pump in their healthcare system, which as a result would boost the market growth. Moreover, the presence of other developed healthcare infrastructure, promising government initiatives in executing weight loss stomach pump in the current healthcare infrastructure, and constantly improving reimbursement scenario would further propel the market growth. Europe was observed to be the second largest market in the weight loss stomach pump owing to enhanced weight loss therapy in the healthcare processes and implementation of stomach pump, a weight loss device in the region.

In June 2016, the U.S. Food and Drug Administration approved a new obesity treatment devices such as Aspire Assist System which is applicable on patients who are moderately overweight. The FDA reviewed results from a clinical trial of 111 patients treated with AspireAssist and appropriate lifestyle therapy. In August 2015, the ORBERA Intragastric Balloon System is a weight-loss system, which uses a gastric balloon that occupies space in the stomach to help patients lose weight. Patients with ORBERA lost an average of 21.8 pounds (10.2% of their body weight) after the device had been in place for six months. The major players operating in this market include Apollo Endosurgery, Inc.( ORBERA® balloon), Aspire Bariatrics, Inc.( AspireAssist System), among other significant players worldwide.

Research Report: http://www.transparencymarketresearch.com/weight-loss-stomach-pump-market.html

The report offers a comprehensive evaluation of the market. It does so via in-depth insights, understanding market evolution by tracking historical developments, and analyzing the present scenario and future projections based on optimistic and likely scenarios. Each research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology developments, types, applications, and the competitive landscape. 

Global Homeopathy Products Market - Increasing Awareness about Herbal Medicines Drives Growth Across the Globe

Homeopathy is alternative medicine, which was established in Germany in the later part of the 18th century. It is based on the idea of ‘Law of Similars’. According to this principle, if a matter can produce symptoms in a healthy individual, it can treat similar symptoms in a sick individual. Homeopathic medicines are composed of natural substances in extremely diluted amounts for the treatment of a number of ailments. These medicines are prepared by repeatedly diluting and vigorous shaking of the original substance preparation in water and alcohol. Post dilution, the medicine is added to pillules or lactose tablets.

Request a Free PDF Brochure with Report Analysis: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=13049

The global homeopathic products market is on the rise due to the increasing demand for homeopathy for the treatment of several diseases. According to the World Health Organization, homeopathy is the second largest medicine system displaying a growth rate of 20-25% each year. This is because homeopathy has reportedly proven to be effective for the treatment of several acute and chronic diseases. Though there is a lack of understanding of working of homeopathic medicines, these medicines are believed to be active and are curative.

The increasing participation of several new players is also leading to the growth of the global homeopathy products market. These players are focused on the utilization of new technologies for the development of more effective products.

North America is the largest regional market for homeopathy products due to several factors. These include increasing preference of individuals for natural and holistic medicine and favorable reimbursement policies for the same. Europe is the second-largest market for homeopathy products. In the U.K., homeopathy is fully recognized as a curative medical practice and is covered by public health insurance. Asia Pacific is emerging as a significant market for homeopathy products due to the rapid advancement of the healthcare industry in emerging economies and the revival of alternative medicine for fewer side-effects. According to a study carried out by the Associated Chambers of Commerce and Industry of India in 2011, the domestic homeopathy market is expected to reach new heights in the coming years.

Some of the leading players in the global homeopathy products market are Hahnemann Laboratories Inc., Natural Health Supply, SBL, Hyland’s Homeopathic, and Nelson & Co. Ltd.

Remote Breathalyzer Market Increasing Alcohol & Drug Abuse Cases Boosted Growth; Global industry Analysis & Forecast upto 2024

From the public safety point of view, it is very important to keep drunk drivers off the roads. As per the data by the Center for Disease Control and Prevention (CDC), in the U.S. alone, approximately 10,000 people die each year in driving crashes due to driving while drunk. A breathalyzer is a device for estimating blood alcohol concentration/content (BAC) from a breath sample. In most of the countries, alcohol intoxication is legally demarcated by the blood alcohol concentration (BAC) level and a driver is prohibited from driving when their blood alcohol concentration (BAC) is .08 grams per deciliter (g/dL) or higher. Withdrawing blood or urine sample at the site and examining it later is not feasible and practical and hence the possibility of estimating BAC indirectly by assessing the amount of alcohol in one's breath poses good market opportunity for these devices. 

View exclusive Global strategic Business report http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=13847 

Remote breathalyzer is a portable electrochemical fuel cell-based instruments used for preliminary breath test (PBT) or preliminary alcohol screening (PAS) which is performed in the field. These devices works on the principle of a chemical reaction between sulfuric acid, potassium dichromate, silver nitrate and water. Alcohol present in the air is absorbed by the sulfuring acid and the solution color changes from reddish orange dichromate ions to green chromium ions. The reaction is catalyzed by the presence of silver nitrate and the degree of the color change is used to quantify the amount of alcohol in the exhaled air. The standard mixture (unreacted) in the photocell system is compared with the reaction mixture to compute the BAC.

On the basis of technology, remote breathalyzers can be classified into three categories: fuel cell testers, semiconductor oxide-based testers, and spectrophotometer testers.  Fuel cell-based breathalyzers are more sensitive and are classified as professional level testers.  They are also portable and give an extremely accurate reading. Fuel cell testers define intoxication levels through the alcohol oxidation in breath samples. The device enables a chemical reaction with alcohol to generate an electric current. The current produced is proportional to amount of alcohol in the blood and used as a measure to scale a persons’ BAC. Spectrophotometer testers are not portable and use infrared light for alcohol detection. Semiconductor oxide-based testers are relatively new to the market and use alcohol-based sensors to estimate alcohol level in blood. However, semiconductor oxide-based testers are not very accurate and are categorized as personal model. The growth of the global remote breathalyzer is mainly driven by increasing alcohol and drug abuse cases and stringent government laws and regulations. Moreover, growing popularity and demand for personal breathalyzers and development of cost-effective alcohol breathalyzers in emerging markets is expected to witness rapid surge in the demand during the forecast period.

The global breathalyzers market has been segmented on the basis of end users into security agencies, hospitals, home care facilities, and rehabilitation centers. Security agencies are the largest end-users of breathalyzers. However, growing personal use of breathalyzers is expected to increase during the forecast period from 2016 to 2024. Geographically, the global remote breathalyzer market can be segmented into five key regions, namely, North America, Europe, Asia Pacific, the Middle East and Africa and Latin America. In past, North America has dominated the market due to enactment and implementation of stringent laws by the government in the region. However, developing nations in Asia Pacific are expected to witness the fastest growth during the forecast period. Growing awareness for drug testing coupled with government initiatives, increased public awareness and reduction in cost are the major drivers for the market growth in these geographies. The major restraint for the market can be violation privacy rights in some countries. High pricing and less opportunities for new market players in developed regions can also be the restraints for the market during the forecast period.

Key players in the market include Alcohol Monitoring Systems, Inc., Alere, Inc., Andatech Private Limited, BACtrack, Drägerwerk AG, Intoximeters, Inc., Lion Laboratories Limited, Lifeloc Technologies, Quest Diagnostics, Soberlink Healthcare LLC.

Global Image Guided Surgery Devices Market to Log 6.40% CAGR 2014-2022 due to Increasing Demand For Enhanced Healthcare Facilities

A new Transparency Market Research report states that the global image guided surgery devices market, which was pegged at US$2.76 bn in 2013, is predicted to reach US$4.80 bn in 2022, expanding at a CAGR of 6.40% from 2014 to 2022. The title of the report is “Image Guided Surgery Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022.”

Image guided surgery is a term utilized for any type of surgical procedure wherein the surgeon utilizes tracked surgical instruments coupled with intraoperative and preoperative images for indirect guidance for the procedure. Image guided surgery systems utilize electromagnetic fields or cameras for capturing and relaying images of the anatomy of patients. Image guided surgery is used in a wide range of applications and is particularly utilized in surgery of the sinuses, where it aids in avoiding damage to the nervous system and the brain of the patient.

Download Free Research PDF: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2541

As per the report, the increasing demand for enhanced healthcare facilities and the rising healthcare expenditure globally are amongst the chief factors fuelling the market for image guided surgery devices. In addition, the rising popularity of IGS devices and the increasing initiatives taken by governments globally will also have a positive impact on the growth of the market. Furthermore, the developing markets hold a significant potential for the image guided surgery devices, hence propelling market development. The increasing count of partnerships and collaborations is a key trend seen in the market. On the other hand, the absence of skilled professionals and the soaring cost of installation of image guided surgery devices are amongst the major factors inhibiting the development of the market. In addition, the stringent regulatory needs and the lack of health insurance in emerging countries will also pose a negative impact on the growth of the market.

On the basis of device type, the report segments the market into ultrasound, computed tomography (CT) scanners, magnetic resonance imaging (MRI) machine, x-ray fluoroscopy machine, endoscope, single photon emission computed tomography (SPECT) equipment, and positron emission tomography (PET) machine. Amongst these, computed tomography (CT) scanners have the highest demand owing to the increasing applications of CT scanners in tumor detection and imaging of soft tissue structures. In addition¸ the turnaround time of these scanners is less, which is advantageous in critical and complicated surgeries. This segment stood at US$770 mn in 2013.

Browse Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2541

In terms of application, the report segments the market into orthopedic surgery, neurosurgery, oncology surgery, ear, nose, and throat surgery, and others. Amongst these, the segment of neurosurgery held the largest share in the market in 2013. The increasing accuracy of operating procedures is a key factor fuelling the growth of the neurosurgery segment. On the other hand, the demand for orthopedic image guided surgeries is also predicted to rise owing to the increasing aging population and the increasing occurrence of road accidents globally.

On the basis of geography, the report segments the market into Europe, North America, Latin America, Asia Pacific, the Middle East, and Rest of the World (RoW). Amongst these, North America led the market in 2013 and was trailed by Europe. The reasons for the superiority of both these regions include the increasing adoption rate of new technologies, the increasing healthcare expenditure, and the availability of trained healthcare professionals in these regions.

As per the report, the chief players dominant in the market are Toshiba Corporation, Siemens Healthcare, Koninklijke Philips N.V., St. Jude Medical, Inc., General Electric Company, Medtronic plc, Brainlab AG, and Varian Medical Systems, Inc., among others.

Implantable Cardioverter Defibrillator Market - Evolving Market Trends and Dynamics 2024

An implantable cardioverter defibrillator is a device that monitors a person's heart rate post its implantation in patients with heart failure. The device continuously monitors your heartbeat and sends electrical pulses to repair a normal heart rhythm when necessary. Implantable cardioverter defibrillator (ICD) or automated implantable cardioverter defibrillators can save patients from arrhythmias by regulating the irregular heartbeats. The device is used in treating sudden cardiac arrest caused due to cardiac arrhythmias, particularly ventricular fibrillation and pulseless ventricular tachycardia. Invention of the implantable cardioverter defibrillator was started by Michel Mirowski in the late 1960s after one of his close friend’s death who was also his mentor and had been admitted to hospital with recurrent ventricular tachyarrhythmias. 

Research Brochure Download: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=13826

The most important factors driving the global implantable cardioverter defibrillators market are increasing incidences of cardiovascular disorders, increasing demand for implantable cardioverter defibrillator from emerging countries of Asia-Pacific and the Middle-East as cardiovascular disorders are increasing and awareness about the disease also increases in these countries, increasing number of training and awareness programs across the globe for Implantable Cardioverter Defibrillators. These training and awareness programs are conducted for the patients as well as the surgeons by Mayo Clinic US.

The implantable cardioverter defibrillators governs the appropriate therapy for returning your heartbeat to a normal heart rhythm. Doctor programs the implantable cardioverter defibrillators to deliver functions such as anti-tachycardia pacing (ATP) and cardio.  A series of small electrical impulses are delivered to the heart muscle to restore a normal heart rate and rhythm. In cardio, a low energy shock is delivered at the same time as your heartbeat to restore a normal heart rhythm. Defibrillation means when the heart is beating dangerously fast, a high-energy shock is delivered to the heart muscle to restore a normal rhythm. Bradycardia pacing means when the heart beats too slow, small electrical impulses are sent to stimulate the heart muscle to maintain a suitable heart rate.

The American Heart Association recommends some guide lines for the person to be eligible for an implantable cardioverter defibrillator.  The arrhythmia in question must be life threatening and the correctable causes of arrhythmia (acute myocardial infarction, myocardial ischemia, electrolyte imbalance and drug toxicity) have been ruled out by doctors have ruled out correctable causes of the arrhythmia.

Get a Research Report: http://www.transparencymarketresearch.com/implantable-cardioverter-defibrillator-market.html

Implantable cardioverter defibrillators market can be segmented by product types, by procedure type, and end user type. Implantable cardioverter defibrillator are categories into single chambered, dual chambered and biventricular implantable cardioverter defibrillators on product types. Based on implantation region ICDs are categorized into trans-venous implantable cardioverter defibrillators and subcutaneous implantable cardioverter defibrillators.The subcutaneous ICD (S-ICD) is placed without inserting the leads inside the heart. The device is placed under the skin below the left axilla, or armpit along the rib cage, and not inserting in the standard location near the collarbone. The lead which is connected to the device is burrowed under the skin rather than inside the heart. The advantages of the S-ICD are that it do not show any of the immediate or long-term complications followed due to placing a lead into the heart, such as perforation of the heart and collapse of the lung. Subcutaneous Implantable Cardioverter Defibrillators is the key driver for the ICD market as it have very less complications and easy implantable procedure. Based on end user type the ICDs are divided into hospital and super specialty hospitals, home users, cardiac catheterization laboratory users and electrophysiology laboratory users. Geographically, the market has been categorized in five main regions: North America, Europe, Latin America, Asia pacific and the Middle East and Africa.

The key implantable cardioverter defibrillators manufacturer companies include Boston Scientific Corporation, Imricor Medical Systems, Inc., LivaNova PLC Company, Mayo Clinic US, Medtronic plc, MicroPort Scientific Corporation, MRI Interventions, Inc., St. Jude Medical, Inc.,

Biopsy Devices Market - Demand for Minimally Invasive Procedures to Pave the Way for Increasing Use of Biopsy Devices

The global biopsy devices market is highly consolidated with four major players collectively accounting for 91% of the total global market, reports Transparency Market Research (TMR) in a new study. The key players are CareFusion Corporation, C R Bard, Inc., Devicor Medical Products, Inc., and Hologic, Inc. A number of small local players supply devices such as forceps, needles, and punches in their respective countries via a crude network of distributors.

“The threat from new entrants is low due to stringent regulatory environment and low financing conditions,” says the author of the study. These factors do not pose a threat to the contribution of aforementioned key players in the global market.

Request a Free Research Sample: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=797

Rising Incidence of Cancer Cases Worldwide Helps Uptake of Biopsy Devices

A growing prevalence of cancer has become a critical issue for governments and international organization such as the WHO. According to a report by the WHO, the number of deaths due to cancer across the globe will show a constant rise and will reach nearly 13.1 bn in 2030. This has led to the initiation of various patient awareness programs by such organizations. As a result, increased number of patients are undergoing biopsies, thereby driving the growth of the market.

Additionally, with a rising geriatric population, the incidence of cancer is also likely to increase. This will serve the global biopsy market as a driver due to the fact that aging increases a person’s susceptibility to cancer.

A surge in the demand for minimally invasive biopsy procedures has been registered owing to the shorter patient recovery span, lesser post-surgery complications and side effects, and minimal pain. They are useful in accurate cancer diagnosis and provide great assistance to physicians to determine the best suitable treatment plan for the patient. This growth driver will have a deep impact on the biopsy devices market.

Reduced Affordability to Restrain Demand for Biopsy Devices

Technological advancements have transformed biopsy devices into higher accuracy products. However, this has also reduced the affordability of these devices. Additionally, the lack of interest of medical practitioners to invest in the capital-intensive market has elevated the cost of these devices. Moreover, the introduction of taxes such as the Medical Device Excise Tax (MDET) of 2.3% in the U.S., will lead to further price hike of products.

Medical reimbursement issues further increase the reluctance of patients to opt for biopsy devices. “Insurance companies do not grant reimbursements for every biopsy procedure as they consider it to be only investigating technique and not a surgical technique,” says a TMR analyst. These issues will negatively influence the growth rate of the global biopsy devices market.

North America Maintains Substantial Lead Owing to Large Pool of Cancer Patients

According to the report by TMR, the valuation of global market for biopsy devices was US$1.34 bn in 2011 and is anticipated to rise to nearly US$2.11 bn by 2018.

Browse Research Report: http://www.transparencymarketresearch.com/biopsy-devices-market.html

The biopsy guidance systems form the leading segment by value in terms of product types. The segment was valued US$767 mn in 2015 and is expected to reach at US$913.5 mn in 2018. However, the needle- based biopsy guns form the fastest growing segment due to their increasing use in biopsy procedures.

By geography, the global biopsy devices market is segmented into Asia, Europe, North America, and Rest of the World (RoW). The growing incidence of cancer has made it the largest regional market by value and is expected to retain its leadership by the end of 2018. The unmet medical needs in Asia coupled with the growing pool of cancer patients has made it the fastest growing region by revenue.

Sales of Spinal Muscular Atrophy Market to Cross US$0.47 globally by the end of 2023, reports TMR

A new report, titled “Spinal Muscular Atrophy Market - Pipeline Assessment, Size, Growth, Trends, and Forecast 2015 - 2023” has been published by Transparency Market Research. The study offers a detailed analysis of the spinal muscular atrophy market, providing insights into the pipeline assessment, major growth drivers, restraints, and potential opportunities. According to the research study, the spinal muscular atrophy phase three candidate ISIS-SMNRx is projected to generate revenue of US$0.47 by the end of 2023 in the U.S.

Request a Free Research Sample: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=7187

Spinal muscular atrophy is genetic neuromuscular disease that is characterized by muscle weakness and atrophy. This disease is the leading genetic cause of death in toddlers and infants, given that it generally manifests early in life. According to the Spinal Muscular Atrophy Association, this disease affects an estimated 10,000 to 25,000 adults and children in the U.S. alone, making it one of the most common rare diseases. The association reveals that an estimated 6 million Americans are carriers of the SMA gene and one in 6,000 to one in 10,000 kids are born with this neuromuscular disease.

The research report offers key insights into the prevalence and current treatment pattern of spinal muscular atrophy, identifying major market drivers, opportunities, and restraints in the global market for spinal muscular atrophy therapeutics. An analysis of market attractiveness with respect to geography takes into consideration several factors such as drug pricing policies, current competition intensity, patient population, regulatory restrictions, and present state of the healthcare sector. This gives readers a clear picture of the potential of each geographical segment of the spinal muscular atrophy market.

The spinal muscular atrophy therapeutics market is segmented into early stage candidates and late stage candidates. Early stage candidates of Phase 1 and Phase 2 include LMI070, CK-2127107, RG3039, Olesoxime (TRO19622), RO6885247, and scAAV9.CB.SMN. Late stage candidates of Phase 3 include ISIS-SMN Rx. This Phase 3 candidate for the treatment of Type 1 and Type 2 SMA is present an annual sales of US$0.4 bn in the US by the end of the forecast period in 2023.

Europe and the US are presently the dominating markets for spinal muscular atrophy therapeutics owing to the fact that these regions have a greater percentage of diagnosed cases of SMA. Private and government organizations have been largely involved in creating awareness about spinal muscular atrophy. In addition, the governments in these regions have been offering incentives for the development of therapeutic options for the treatment of rare diseases, which in turn boosts research and development in the field of spinal muscular atrophy.

The major companies competing in this space are F. Hoffmann-La Roche Ltd., Isis Pharmaceuticals, Inc., AveXis, Inc., Cytokinetics, Inc., and Novartis AG, and these players have been profiled in the report with the help of several market intelligence tools. Their strengths, weaknesses, opportunities, and threats have been evaluated, along with a detailed assessment of their product offerings.

Selective Serotonin Reuptake Inhibitors Market - Latest trends in Pharmaceutical Industry; Market Forecasts by 2024

Selective serotonin reuptake inhibitors (SSRIs) elevate the extracellular level of neurotransmitters known as serotonin by inhibiting its uptake in presynaptic cells. Therefore, selective serotonin reuptake inhibitors are widely used as medication for the treatment of severe or persistent depression. In addition, selective serotonin reuptake inhibitors are also used in combination with therapies such as cognitive behavioral therapy (CBT).

Download PDF of Premium Research Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=13343

Furthermore, selective serotonin reuptake inhibitors are also used for mental conditions such as panic disorders, obsessive compulsive disorder (OCD), post-traumatic stress disorder (PTSD), severe phobias, including social phobia and agoraphobia, and generalized anxiety disorder (GAD). In addition, selective serotonin reuptake inhibitors are also used for the treatment of premenstrual syndrome, premature ejaculation, irritable bowel syndrome and fibromyalgia. Side effects of selective serotonin reuptake inhibitors include, low sex drive, dizziness, sickness, anxiety, erectile dysfunction in male population and blurred vision.

According to the World Health Organization (WHO), depression is the fourth leading cause of deaths and by 2020; it is expected to be the second leading cause of deaths worldwide. According to the National Institute of Mental Health (NIHM), part of National Institute of Health (NIH) of the U.S., in 2012, around 16 million adults above 18 years of age had at least one major depressive episode in the past year in the U.S. Risk of depression is twice in women population.

Get a Research Report: http://www.transparencymarketresearch.com/selective-serotonin-reuptake-inhibitors-market.html

According to the Depression and Bipolar Support Alliance, the lifetime prevalence for female population is 20% to 26%. While life time prevalence of depression for male population is 8% to 12%. According to the article published by the British Psychology Society in June 2013, finding from the Office for National Statistics (ONS) states that approximately one fifth of the overall adult population experience depression. Thus, perpetually rising prevalence depression worldwide is the major factor driving the growth of the global selective serotonin reuptake inhibitors (SSRIs) market.

Geographically, the selective serotonin reuptake inhibitors market is segmented into North America, Europe, Asia Pacific and Rest of the World (RoW). Presently, Europe and North America are dominating the global selective serotonin reuptake inhibitors (SSRIs) market. Factors such as, divorce, unemployment, work pressure, and higher life expectations are resulting in higher rate of depression cases.